The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Treatment patterns, mortality, and costs of care in unfit patients (pts) with relapsed chronic lymphocytic leukemia (CLL).
Helen Varker
No relevant relationships to disclose
Xue Song
Research Funding - Truven Health Analytics
Nicole Meyer
Research Funding - Truven Health Analytics
Stephanie A. Gregory
Consultant or Advisory Role - Gilead Sciences
Javier Pinilla-Ibarz
Consultant or Advisory Role - Gilead Sciences
Scott David Ramsey
Consultant or Advisory Role - Gilead Sciences